Technical Analysis for AGIO - Agios Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| A | 31.49 | -0.57% | -0.18 |
Earnings due: May 2
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Upper Bollinger Band Walk | Strength | -0.57% | |
| Upper Bollinger Band Touch | Strength | -0.57% | |
| Gapped Down | Weakness | -0.57% | |
| Upper Bollinger Band Walk | Strength | -0.57% | |
| Inside Day | Range Contraction | -0.57% | |
| Above Upper BB | Strength | -0.57% | |
| Upper Bollinger Band Touch | Strength | -0.57% |
| Alert | Time |
|---|---|
| Possible NR7 | about 11 hours ago |
| Possible Inside Day | about 11 hours ago |
| Up 1% | about 15 hours ago |
| Upper Bollinger Band Resistance | about 15 hours ago |
| Down 1% | about 15 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/02/2024
Agios Pharmaceuticals, Inc. Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its products include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations; and enzyme glutaminase that converts the nutrient glutamine into the metabolite glutamate. The company's products also comprise AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation. The company was founded in 2007 and is based in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Acid Hydrogen Metabolism Organic Chemistry Glutamate Inborn Errors Of Metabolism Pyruvate Kinase Deficiency
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 35.5 |
| 52 Week Low | 19.795 |
| Average Volume | 761,029 |
| 200-Day Moving Average | 25.56 |
| 50-Day Moving Average | 30.06 |
| 20-Day Moving Average | 29.59 |
| 10-Day Moving Average | 30.29 |
| Average True Range | 1.20 |
| RSI (14) | 62.69 |
| ADX | 22.38 |
| +DI | 27.39 |
| -DI | 11.46 |
| Chandelier Exit (Long, 3 ATRs) | 29.41 |
| Chandelier Exit (Short, 3 ATRs) | 30.75 |
| Upper Bollinger Bands | 32.16 |
| Lower Bollinger Band | 27.02 |
| Percent B (%b) | 0.87 |
| BandWidth | 17.37 |
| MACD Line | 0.57 |
| MACD Signal Line | 0.29 |
| MACD Histogram | 0.2782 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 32.54 | ||||
| Resistance 3 (R3) | 32.60 | 32.30 | 32.37 | ||
| Resistance 2 (R2) | 32.30 | 32.04 | 32.28 | 32.31 | |
| Resistance 1 (R1) | 31.90 | 31.87 | 31.75 | 31.84 | 32.25 |
| Pivot Point | 31.60 | 31.60 | 31.53 | 31.58 | 31.60 |
| Support 1 (S1) | 31.20 | 31.34 | 31.05 | 31.14 | 30.73 |
| Support 2 (S2) | 30.90 | 31.17 | 30.88 | 30.67 | |
| Support 3 (S3) | 30.50 | 30.90 | 30.62 | ||
| Support 4 (S4) | 30.44 |
